


## Ozagrel sodium

Cat. No.:	HY-B0428A		
CAS No.:	189224-26-8		
Molecular Formula:	C <sub>13</sub> H <sub>11</sub> N <sub>2</sub> NaO <sub>2</sub>		
Molecular Weight:	250.23		
Target:	Prostaglandin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (199.82 mM; Need ultrasonic)  
 DMSO : 6.25 mg/mL (24.98 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.9963 mL	19.9816 mL	39.9632 mL
	5 mM	0.7993 mL	3.9963 mL	7.9926 mL
	10 mM	0.3996 mL	1.9982 mL	3.9963 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 0.62 mg/mL (2.48 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 0.62 mg/mL (2.48 mM); Clear solution
- Add each solvent one by one: PBS  
 Solubility: 70 mg/mL (279.74 mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Ozagrel sodium (OKY-046 sodium) is a thromboxane A<sub>2</sub> (TXA<sub>2</sub>) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC<sub>50</sub> of 53.12 μM<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

TXA<sub>2</sub>

---

## REFERENCES

---

[1]. Max Seidy Saito, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31(6):1591-601.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA